RxSight CMO Ronald Kurtz sells $35,496 in shares for tax

Dr. Ronald M. Kurtz, Chief Medical Officer of RxSight, Inc. (NASDAQ:RXST), sold 5,100 shares of common stock on September 2, 2026, at a price of $6.96 per share, totaling $35,496. This transaction was executed to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) and does not represent a discretionary sale by Dr. Kurtz. The stock currently trades at $7.03, and according to InvestingPro analysis, appears undervalued with a Fair Value of $8.62.

The sale followed the acquisition of 13,425 shares of common stock on August 31, 2026, through the vesting of RSUs. Each restricted stock unit represents a contingent right to receive one share of the Issuer’s Common Stock.

Following these transactions, Dr. Kurtz directly beneficially owns 71,775 shares of RxSight common stock. Additionally, he indirectly holds 764,610 shares through Cricklewood LP. Dr. Kurtz serves as the manager of the general partner of Cricklewood LP and shares voting and investment control with his spouse. The medical device company maintains a strong balance sheet with more cash than debt, though analysts don’t anticipate profitability this year, according to InvestingPro Tips.

In other recent news, RxSight reported its second-quarter 2026 earnings, surpassing Wall Street expectations. The company posted an adjusted loss of $0.11 per share, which was significantly better than the anticipated loss of $0.36 per share. Revenue for the quarter reached $33.74 million, exceeding the forecasted $32.21 million. Despite this positive performance, RxSight withdrew its full-year guidance, citing ongoing challenges in its core business. Additionally, Stifel has lowered its price target for RxSight to $7.00 from $8.00, while maintaining a Hold rating on the stock. This adjustment follows the company’s pre-announcement of weak second-quarter results and a new collaboration with ALC. Stifel’s analysis suggests that the withdrawn guidance does not necessarily indicate worsening trends, as improvements have been observed quarter-to-date.